journal
MENU ▼
Read by QxMD icon Read
search

Annals of Hematology

journal
https://www.readbyqxmd.com/read/30030570/characteristics-of-pulmonary-complications-in-non-hodgkin-s-lymphoma-patients-treated-with-rituximab-containing-chemotherapy-and-impact-on-survival
#1
Kimberly Keefer, Regis Bender, Jason Liao, Jeffrey Sivik, Andry Van de Louw
Patients with non-Hodgkin's lymphoma (NHL) receiving rituximab-containing chemotherapy are at risk of developing respiratory complications, but comprehensive information on these complications and their impact on survival is lacking. We performed a retrospective cohort analysis on 123 NHL patients who received rituximab-containing chemotherapy between 2009 and 2016 in order to describe the incidence, etiologies and effect on survival of respiratory complications defined by new or worsening respiratory symptoms requiring diagnostic work-up or hospitalization...
July 21, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30030569/cytogenetically-cryptic-insertion-of-pml-segment-into-rara-on-chromosome-17q-resulting-pml-rara-fusion-in-acute-promyelocytic-leukemia
#2
LETTER
Timothy F Burns, Eric Y Loo, Elizabeth M Bengtson, Liming Bao
No abstract text is available yet for this article.
July 20, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30027436/long-term-follow-up-of-a-single-institution-pilot-study-of-sirolimus-tacrolimus-and-short-course-methotrexate-for-graft-versus-host-disease-prophylaxis-in-mismatched-unrelated-donor-allogeneic-stem-cell-transplantation
#3
LETTER
Tae Kon Kim, Michelle DeVeaux, Maximilian Stahl, Sarah Perreault, Iris Isufi, Dennis Cooper, Francine Foss, Warren Shlomchik, Daniel Zelterman, Amer M Zeidan, Stuart Seropian
No abstract text is available yet for this article.
July 19, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30027435/the-role-of-bortezomib-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-a-meta-analysis
#4
Zhijuan Lin, Xing Chen, Zhifeng Li, Yong Zhou, Zhihong Fang, Yiming Luo, Jintao Zhao, Bing Xu
Although the survival rate of diffuse large B cell lymphoma (DLBCL) has increased with years, there are still patients who do not achieve complete remission or who relapse, especially patients with activated B cell-like (ABC) DLBCL. Bortezomib, a proteasome inhibitor, has shown activity in diffuse large B cell lymphoma, especially in the subtype of ABC DLBCL. We conducted a meta-analysis to compare the efficacy and adverse events in bortezomib-containing regimens with standard R-CHOP regimen in treating DLBCL...
July 19, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30022221/high-ets2-expression-predicts-poor-prognosis-in-acute-myeloid-leukemia-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#5
LETTER
Gaoqi Zhang, Lingxiu Zhang, Xinrui Yang, Xinpei Zhang, Jilei Zhang, Siyuan Yang, Jing Wang, Kai Hu, Jinlong Shi, Xiaoyan Ke, Lin Fu
No abstract text is available yet for this article.
July 18, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30019128/pd-1-genotype-of-the-donor-is-associated-with-acute-graft-versus-host-disease-after-hla-identical-sibling-donor-stem-cell-transplantation
#6
Nazly Santos, Rocío Rodríguez-Romanos, Rafael de la Cámara, Salut Brunet, Jose B Nieto, Ismael Buño, Carmen Martínez, Antonio Jiménez-Velasco, Carlos Vallejo, Marcos González, Carlos Solano, Christelle Ferrá, Antonia Sampol, Jose A Pérez-Simón, Javier López-Jiménez, José L Díez, David Gallardo
Programmed death 1 (PD-1) activation triggers an immune checkpoint resulting in inhibition of T cells that leads to peripheral tolerance. Some PD-1 polymorphisms have been described and associated with the development of autoimmune diseases or cancer predisposition, but there are few data concerning the relevance of such polymorphisms on the clinical outcome after allogeneic hematopoietic stem cell transplant (alloHSCT). We analyzed the distribution of the SNPs PD-1.1G/A (rs36084323) and PD-1.3G/A (rs11568821) genotypes of the donor in a cohort of 1485 alloHSCT from HLA-identical sibling donors...
July 17, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30009341/molecular-remission-at-the-end-of-treatment-is-a-necessary-goal-for-a-good-outcome-in-eln-favorable-risk-acute-myeloid-leukemia-a-real-life-analysis-on-201-patients-by-the-rete-ematologica-lombarda-network
#7
Patrizia Zappasodi, Laura Marbello, Erika Borlenghi, Monica Fumagalli, Massimo Bernardi, Nicola Fracchiolla, Valentina Mancini, Matteo Da Vià, Emanuele Ravano, Elisa Cerqui, Virginia Valeria Ferretti, Barbara Rocca, Celeste Calvello, Mario Cazzola, Carlo Castagnola, Giuseppe Rossi
Favorable acute myeloid leukemia (AML) patients (pts.) demonstrate a relatively good outcome with standard induction; thus, pts. are generally not addressed to allogeneic transplant in first remission. However, it is not clear if also in a real-life setting, the outcome is homogeneous in the different favorable molecular groups and which are the parameters significantly associated to an increased relapse risk, useful to suggest the need of an intensified approach. In order to clarify this point, we collected clinical data on consecutive unselected AML pts...
July 15, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30003318/comparison-of-argatroban-and-fondaparinux-for-the-management-of-patients-with-isolated-heparin-induced-thrombocytopenia
#8
Fahad A S Al-Eidan, Saud Alrawkan, Huda Alshammary, Mark A Crowther
Heparin-induced thrombocytopenia (HIT) is a serious complication of the administration of heparin and its derivatives. Non-heparin anticoagulants such as argatroban and fondaparinux are widely used in the management of HIT to compare the effectiveness of argatroban and fondaparinux in the resolution of thrombocytopenia and to compare clinical outcomes in patients with isolated HIT. A retrospective cohort analysis was performed at King Abdulaziz Medical City (KAMC) on patients diagnosed with isolated HIT between 31 Jan, 2014 and 30 June, 2017...
July 12, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30003317/langerhans-cell-histiocytosis-associated-with-classical-hodgkin-lymphoma-contains-braf-v600e-mutation
#9
LETTER
Shanxiang Zhang, Julia Steinhilber, Falko Fend
No abstract text is available yet for this article.
July 12, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29995264/effects-of-preemptive-interferon-%C3%AE-monotherapy-in-acute-leukemia-patients-with-relapse-tendency-after-allogeneic-hematopoietic-stem-cell-transplantation-a-case-control-study
#10
Xiao-Ji Lin, Hai-Ping Dai, Ai-Jing Wang, Feng Chen, Xiao Ma, Ai-Ning Sun, Xia-Ming Zhu, Hui-Ying Qiu, Zheng-Min Jin, Miao Miao, Sheng-Li Xue, Xin-Liang Mao, De-Pei Wu, Xiao-Wen Tang
Interferon-α (IFN-α) inhibits tumor growth and mimics graft-versus-leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the current case-control study, we compared treatment responses in acute leukemia patients with relapse tendency post-allo-HSCT receiving preemptive IFN-α after withdrawal of immunosuppressants (n = 31) vs. receiving no IFN-α (n = 67). In the IFN-α group, 25 patients responded to the treatment without progressing to hematological relapse. In the non-IFN-α group, only 22 patients responded to the treatment...
July 11, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29987351/a-case-of-reversible-cerebral-vasoconstriction-syndrome-developing-during-treatment-of-adult-aplastic-anemia
#11
LETTER
Akira Yamamoto, Yusuke Meguri, Akiko Fukuda, Yui Kambara, Tomohiro Urata, Taiga Kuroi, Taro Masunari, Nobuo Sezaki, Toru Kiguchi
No abstract text is available yet for this article.
July 10, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29987350/haplo-identical-allografting-with-post-transplant-cyclophosphamide-in-high-risk-patients
#12
Lucia Brunello, Roberto Passera, Chiara Maria Dellacasa, Luisa Giaccone, Ernesta Audisio, Dario Ferrero, Stefano D'Ardia, Bernardino Allione, Semra Aydin, Moreno Festuccia, Giuseppe Lia, Elena Crisà, Enrico Maffini, Sara Butera, Alessandro Busca, Benedetto Bruno
Haplo-identical transplants (Haplo-Tx) are an important alternative for patients with hematological malignancies who lack a HLA-identical donor. Seventy-one T-replete Haplo-Tx were performed in 70 high-risk patients at our center; 22/70 (31%) patients with refractory/relapsed leukemia received sequential salvage therapy (SeqTh) with high-dose chemotherapy followed by Haplo-Tx during the chemotherapy-induced neutropenia. Graft-versus-host disease (GVHD) prophylaxis consisted of post-transplant cyclophosphamide (days + 3 and + 4) with tacrolimus and mycophenolic acid...
July 9, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29982851/successful-treatment-of-refractory-relapsed-acquired-pure-red-cell-aplasia-with-sirolimus
#13
Zhangbiao Long, Fan Yu, Yali Du, Hongmin Li, Miao Chen, Junling Zhuang, Bing Han
Acquired pure red cell aplasia (aPRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Some patients are refractory or intolerant to the first-line therapy (cyclosporine A with/without steroids). The effects of the second-line therapy are not satisfactory and sometimes not available. In this study, we analyzed the efficacy and side effect of sirolimus on refractory/relapsed aPRCA and investigated the possible mechanism of sirolimus on immune regulation...
July 7, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29982850/coincidence-of-lymphomatoid-granulomatosis-chronic-myelomonocytic-leukemia-and-anaplastic-t-cell-lymphoma-after-methotrexate-therapy-for-rheumatoid-arthritis
#14
LETTER
Rucha Dugge, Hans Kreipe, Andreas Rosenwald, Ulrich Lehmann, Peter Möller, Thomas F E Barth, Rainer Erlemann
No abstract text is available yet for this article.
July 7, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29980875/structural-modeling-of-a-novel-terc-variant-in-a-patient-with-aplastic-anemia-and-short-telomeres
#15
LETTER
M Rinelli, E Bellacchio, F Berardinelli, G Pascolini, P Grammatico, A Sgura, A P Iori, L Quattrocchi, A Novelli, S Majore, E Agolini
No abstract text is available yet for this article.
July 6, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29980874/long-term-remission-of-refractory-rosai-dorfman-disease-after-salvage-therapy-with-clofarabine-in-an-adult-patient
#16
LETTER
Clemens Hinterleitner, Martina Steurer, Daniela Dörfel, Jonas Heitmann, Klaus-Peter Kreisselmeier, Karin Müller, Hans-Georg Kopp, Stefan Wirths, Michael Haap, Leticia Quintanilla-Martinez de Fend, Marius Horger, Carlos Rodriguez-Galindo, Lothar Kanz, Martin R Müller
No abstract text is available yet for this article.
July 6, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29978286/allogeneic-hematopoietic-cell-transplantation-in-adult-acute-myeloid-leukemia-with-11q23-abnormality-a-retrospective-study-of-the-adult-acute-myeloid-leukemia-working-group-of-the-japan-society-for-hematopoietic-cell-transplantation-jshct
#17
Takaaki Konuma, Shohei Mizuno, Tadakazu Kondo, Hiroki Yamaguchi, Takahiro Fukuda, Naoyuki Uchida, Yuho Najima, Heiwa Kanamori, Shuichi Ota, Hirohisa Nakamae, Mika Nakamae, Ishikazu Mizuno, Junichi Sugita, Yasushi Onishi, Akira Yokota, Satoshi Takahashi, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Shingo Yano
An 11q23 abnormality presents in approximately 5% of adults with acute myeloid leukemia (AML) and is associated with adverse outcomes even after allogeneic hematopoietic cell transplantation (allo-HCT). To evaluate the outcomes and prognostic factors following allo-HCT for adult AML with 11q23 abnormality, we retrospectively analyzed the Japanese registration data of 322 adult AML patients with 11q23 abnormality who had received allo-HCT between 1990 and 2014. In total, the disease status at HCT was first complete remission (CR1) in 159 (49%) patients...
July 6, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29978285/cytotoxic-t-lymphocyte-associated-antigen-4-positive-aggressive-adult-t-cell-leukemia-lymphoma
#18
LETTER
Sanae Sueda, Shoko Nakayama, Tatsuya Adachi, Yuka Ohashi, Sumie Awaji, Shigeo Hashimoto, Itaru Matsumura, Mitsuhiro Matsuda
No abstract text is available yet for this article.
July 6, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29978284/rabbit-antithymocyte-globulin-dose-does-not-affect-response-or-survival-as-first-line-therapy-for-acquired-aplastic-anemia-a-multicenter-retrospective-study
#19
Diego V Clé, Elias H Atta, Danielle S P Dias, Carlos B L Lima, Mariana Bonduel, Gabriela Sciuccati, Larissa A Medeiros, Michel M de Oliveira, Patricia B Blum Fonseca, Sara T O Saad, Nelson Hamerschlak, Marco A Salvino, Marlene P Garanito, Antonio Pazin-Filho, Phillip Scheinberg, Rodrigo T Calado
In a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian, South American, and European countries, where r-ATG became the only ATG formulation available. We retrospectively evaluated consecutive patients with acquired AA who received either rabbit (n = 170) or horse (n = 85) ATG and cyclosporine for first-line treatment from 1992 to 2014 in seven referral centers in Brazil and Argentina...
July 5, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29974231/multicenter-phase-1-2-study-of-forodesine-in-patients-with-relapsed-peripheral-t-cell-lymphoma
#20
Dai Maruyama, Kunihiro Tsukasaki, Toshiki Uchida, Yoshinobu Maeda, Hirohiko Shibayama, Hirokazu Nagai, Mitsutoshi Kurosawa, Yoko Suehiro, Kiyohiko Hatake, Kiyoshi Ando, Isao Yoshida, Michihiro Hidaka, Tohru Murayama, Yoko Okitsu, Norifumi Tsukamoto, Masafumi Taniwaki, Junji Suzumiya, Kazuo Tamura, Takahiro Yamauchi, Ryuzo Ueda, Kensei Tobinai
Peripheral T cell lymphomas are an aggressive group of non-Hodgkin lymphomas with poor outcomes for most subtypes and no accepted standard of care for relapsed patients. This study evaluated the efficacy and safety of forodesine, a novel purine nucleoside phosphorylase inhibitor, in patients with relapsed peripheral T cell lymphomas. Patients with histologically confirmed disease, progression after ≥ 1 prior treatment, and an objective response to last treatment received oral forodesine 300 mg twice-daily...
July 5, 2018: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"